Total views : 285

Pharmacoeconomic Evaluation in End Stage Renal Diseased Patients


  • Department of Pharmacology, Sultan-ul-Uloom College of Pharmacy, Mount Peasant, 8-2-249, Road No. 3, Banjara Hills, Hyderabad-34, Telangana State, India
  • Department of Pharmacology, Krupanidhi College of Pharmacy, Chikkabellandur, Carmelaram Post, Bangalore-35, Karnataka, India


Aim : The purpose of this project is to evaluate the economic evaluation of End Stage Renal Diseased patients within the context of continued economic uncertainty and pressure on healthcare resource use. Objective : These findings are important to find out the impact of cost of haemodialysis on patients suffering from ESRD. Further studies related to costs and outcome, otherwise known as pharmacoeconomic studies, are needed to analyse the cost evaluation in End Stage Renal Dialysis patients. 

Methodology : A prospective observational study was conducted for a period of Eight months (December 2015 to July 2016) at a tertiary care hospital in the Inpatient Nephrology Department. Patients coming on outpatient basis were selected for the study. Patients were allotted in different shifts either in morning, afternoon or evening, based on their preferences. The patients were followed up for a period of 8 months. The patient sociodemographics, cost details of dialysis, hospital costs, comorbities diseases and their cost, adverse reactions occurred during dialysis, cost to manage such adverse reactions, regularity, affordability, outcome and patient satisfaction to dialysis, etc. were collected prospectively. 

Result : The total cost per session was found to be around INR 4500. Fifty six percent contributes direct medical cost whereas 20% contributes direct non medical cost. Twenty four percent cost was due to indirect costs. Since the patients are paying from their own pocket, only the upper or upper middle class patient can undergo haemodialysis regularly.


Cost Analysis, End Stage Renal Disease, Haemodialysis, Pharmacoeconomics.

Full Text:

 |  (PDF views: 82)


  • Mani MK. Prevention of chronic renal failure at the community level. Kidney Int. 2003; 83: S86–S89.
  • Agarwal SK, Dash SC, Irshad M, Raju S, Singh R, Pandey RM. Prevalence of chronic renal failure in adults in Delhi, India. Nephrol Dial Transplant. 2005; 20:1638–42.
  • Agarwal SK, Dash SC. Spectrum of renal diseases in India in adults. J Assoc Physicians India.2000; 48: 594–600.
  • Modi GK and Jah V. The incidence of end-stage renal disease in India: A population-based study. Kidney International. 2006; 70 (12): 2131–2133.
  • Mani MK. Chronic renal failure in India. Nephrol Dial Transplant. 1993; 8: 684–689.
  • Mittal S, Kher V, Gulati S . Chronic renal failure in India. Ren Fail. 1997; 19: 753–770
  • Sakhuja V, Jha V, Ghosh AK. Chronic renal failure in India. Nephrol Dial Transplant. 1994; 9: 871–872
  • Suja R, Anju V, Anju J, Neethu P, Peeyush, Saraswathy R. Economic evaluation of end stage renal disease patients undergoing hemodialysis. J Pharm Bioallied Sci. 2012; 4(2): 107–111.
  • Surendra G. Pharmacoeconomics: A review. Asian Journal of Pharmaceutical and Clinical Research. 2009; 2(3): 15-26.
  • Devi P, Rao M, Sigamani A. Prevalence, risk factors and awareness of hypertension in India: a systematic review. J Hum Hypertens. 2013; 27: 281–287.
  • Al-Ramahi R. Medication prescribing patterns among chronic kidney disease patients in a hospital in Malaysia. Saudi J Kidney Dis Transp. 2012; 23: 403-408.
  • Bajait CS, Pimpalkhute SA, Sontakke SD, Jaiswal KM, Dawri AV. Prescribing pattern of medicines in chronic kidney disease with emphasis on phosphate binders. Indian J Pharmacol. 2014; 46: 35-39.
  • Becker G, Wheeler D, Zeeuw D. Kdigo. Clinical practices guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2012; 2: S337-414.